Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models

Cancer Chemotherapy and Pharmacology

Volumn 55, Issue 5, 2005, Pages 411-419

  Woo, Michael H ^a   Peterson, Jennifer K ^b   Billups, Catherine ^b   Liang, Hua ^b   Bjornsti, Mary Ann ^b   Houghton, Peter J ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Irinotecan; Irofulven; Pediatrics; Solid tumors; Xenografts

Indexed keywords

CYTOTOXIC AGENT; IRINOTECAN; IROFULVEN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CHILDHOOD CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOMA; RHABDOMYOSARCOMA; SOLID TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; MICE; MICE, INBRED ICR; SESQUITERPENES; TREATMENT FAILURE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 17644385533     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0902-2     Document Type: Article

References (32)

1. Britten CD, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S (1999) Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res 59:1049
2. Douglass EC, Valentine M, Etcubanas E, Parham D, Webber BL, Houghton PJ, Houghton JA, Green AA (1987) A specific chromosomal abnormality in rhabdomyosarcoma. Cytogenet Cell Genet 45:148
3. Eckhardt SG, Baker SD, Britten CD, Hidalgo M, Siu L, Hammond LA, Villalona-Calero MA, Felton S, Drengler R, Kuhn JG, Clark GM, Smith SL, MacDonald JR, Smith C, Moczygemba J, Weitman S, Von Hoff DD, Rowinsky EK (2000) Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies. J Clin Oncol 18:4086
4. Friedman HS, Colvin OM, Skapek SX, Ludeman SM, Elion GB, Schold SC Jr, Jacobsen PF, Muhlbaier LH, Bigner DD (1988) Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res 48:4189
5. Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffman FA, Meyer WH, Pappo AS, Walter AW, Houghton PJ (1999) Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17:1815
6. Hammond LA, Hilsenbeck SG, Eckhardt SG, Marty J, Mangold G, MacDonald JR, Rowinsky EK, Von Hoff DD, Weitman S (2000) Enhanced antitumour activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model. Eur J Cancer 36:2430
7. Hazelton BJ, Houghton JA, Parham DM, Douglass EC, Torrance PM, Holt H, Houghton PJ (1987) Characterization of cell lines derived from xenografts of childhood rhabdomyosarcoma. Cancer Res 47:4501
8. Hochberg Y, Tamhane A (1987) Multiple comparison procedures. Wiley, New York, p 94
9. Houghton JA, Houghton PJ, Webber BL (1982) Growth and characterization of childhood rhabdomyosarcomas as xenografts. J Natl Cancer Inst 68:437
10. Houghton PJ, Cheshire PJ, Hallman JC, Bissery MC, Mathieu-Boué A, Houghton JA (1993) Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10- hydroxycamptothecin. Cancer Res 53:2823
11. Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Friedman HS, Danks MK, Houghton JA (1995) Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 36:393
12. Izbicka E, Davidson K, Lawrence R, Cote R, MacDonald JR, Von Hoff DD (1999) Cytotoxic effects of MGI 114 are independent of tumor p53 or p21 expression. Anticancer Res 19:1299
13. Jaspers NG, Raams A, Kelner MJ, Ng JM, Yamashita YM, Takeda S, McMorris TC, Hoeijmakers JH (2002) Anti-tumour compounds illudin S and Irofulven induce DNA lesions ignored by global repair and exclusively processed by transcription- and replication-coupled repair pathways. DNA Repair (Amst) 1:1027
14. Kelner MJ, McMorris TC, Estes L, Wang W, Samson KM, Taetle R (1996) Efficacy of HMAF (MGI-I) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional anticancer agents. Invest New Drugs 14:161
15. Kelner MJ, McMorris TC, Estes L, Samson KM, Bagnell RD, Taetle R (1998) Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung carcinoma xenograft. Eur J Cancer 34:908
16. Kelner MJ, McMorris TC, Montoya MA, Estes L, Uglik SF, Rutherford M, Samson KM, Bagnell RD, Taetle R (1999) Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines. Cancer Chemother Pharmacol 44:235
17. Kelner MJ, McMorris TC, Estes LA, Oval MY, Rojas RJ, Lynn JR, Lanham KA, Samson KM (2000) Efficacy of MGI 4 (HMAF) against the MRP+ metastatic MV522 lung carcinoma xenograft. Anticancer Drugs 11:217
18. Kelner MJ, McMorris TC, Estes L, Samson KM, Trani NA, MacDonald JR (2000) Anti-leukemic action of the novel agent MGI 1 (HMAF) and synergistic action with topotecan. Leukemia 14:136
19. Kelner MJ, McMorris TC, Rojas RJ, Trani NA, Velasco TR, Estes LA, Suthipinijtham P (2002) Enhanced antitumor activity of irofulven in combination with antimitotic agents. Invest New Drugs 20:271
20. Kelner MJ, McMorris TC, Rojas RJ, Trani NA, Estes L (2002) Enhanced antitumor activity of irofulven in combination with thiotepa or mitomycin C. Cancer Chemother Pharmacol 49:412
21. Leggas M, Stewart CF, Woo MH, Fouladi M, Cheshire PJ, Peterson JK, Friedman HS, Billups C, Houghton PJ (2002) Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res 8:3000
22. Liefshitz B, Steinlauf R, Friedl A, Eckardt-Schupp F, Kupiec M (1998) Genetic interactions between mutants of the 'error-prone' repair group of Saccharomyces cerevisiae and their effect on recombination and mutagenesis. Mutat Res 407:135
23. MacDonald JR, Muscoplat CC, Dexter DL, Mangold GL, Chen SF, Kelner MJ, McMorris TC, Von Hoff DD (1997) Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res 57:279
24. McMorris TC (1999) Discovery and development of sesquiterpenoid derived hydroxymethylacylfulvene: a new anticancer drug. Bioorg Med Chem 7:881
25. McMorris TC, Kelner MJ, Wang W, Yu J, Estes LA, Taetle R (1996) (Hydroxymethyl) acylfulvene: an illudin derivative with superior antitumor properties. J Nat Prod 59:896
26. McMorris TC, Yu J, Estes LA, Kelner MJ (1997) Reaction of antitumor hydroxymethylacylfulvene (HMAF) with thiols. Tetrahedron 53:14579
27. Poindessous V, Koeppel F, Raymond E, Cvitkovic E, Waters SJ, Larsen AK (2003) Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells. Int J Oncol 23:1347
28. Sarosy GA, Kotz H, Smith S, Murgo A, Minasian L, Dyer V, Kohler D, Kim S, Reed E (2001) Phase II study of irofulven in platinum resistant recurrent ovarian cancer (abstract 868). Proc ASCO 20:218a
29. Thompson J, Zamboni WC, Chesire PJ, Lutz L, Luo X, Li Y, Houghton JA, Houghton PJ (1997) Efficacy of systemic administration of irinotecan against neuroblastoma xenografts. Clin Cancer Res 3:42
30. Weitman S, Barrera H, Moore R, Gonzalez C, Marty J, Hilsenbeck S, MacDonald JR, Waters SJ, Von Hoff D (2000) MGI 114: augmentation of antitumor activity when combined with topotecan. J Pediatr Hematol Oncol 22:306
31. Woynarowska BA, Woynarowski JM, Herzig MC, Roberts K, Higdon AL, MacDonald JR (2000) Differential cytotoxicity and induction of apoptosis in tumor and normal cells by hydroxymethylacylfulvene (HMAF). Biochem Pharmacol 59:1217
32. Woynarowski JM, Napier C, Koester SK, Chen SF, Troyer D, Chapman W, MacDonald JR (1997) Effects on DNA integrity and apoptosis induction by a novel antitumor sesquiterpene drug, 6-hydroxymethylacylfulvene (HMAF, MGI 114). Biochem Pharmacol 54:1181